Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £315.49B | 28.2x | 1.31 | GBX 7,096.12 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie Inc | London | Healthcare | Pharmaceuticals | £292.85B | 88.3x | -7.5 | GBX 17,084.08 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | London | Healthcare | Pharmaceuticals | £223.82B | 30.9x | -1.04 | GBX 28,156.68 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding Participation | London | Healthcare | Pharmaceuticals | £223.82B | 30.9x | -1.03 | GBX 26,316.94 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £184.95B | 33.4x | 1.83 | GBX 11,904 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.1% Upside | Upgrade to Pro+ | |
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £183.69B | 13.7x | 0 | GBX 7,274.52 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | £171.28B | 18.6x | -1.03 | GBX 8,607.32 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | London | Healthcare | Pharmaceuticals | £113.85B | 301.5x | -3.23 | GBX 9,126.72 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi L | London | Healthcare | Pharmaceuticals | £111.25B | 23.7x | 8.09 | GBX 8,880.03 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | London | Healthcare | Pharmaceuticals | £60.47B | 23.5x | -0.48 | GBX 1,479.50 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.1% Upside | Upgrade to Pro+ | |
Merck KGaA | London | Healthcare | Pharmaceuticals | £49.73B | 22.3x | -3.13 | GBX 11,431.69 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON | London | Healthcare | Pharmaceuticals | £36.07B | 24.4x | 0.64 | GBX 410.60 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.4% Upside | Upgrade to Pro+ | |
UCB L | London | Healthcare | Pharmaceuticals | £30.01B | 34.1x | 0.15 | GBX 15,796.17 | 5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bayer L | London | Healthcare | Pharmaceuticals | £19.43B | -26.8x | -0.33 | GBX 1,987.01 | 6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen | London | Healthcare | Pharmaceuticals | £16.26B | 12.6x | 0.31 | GBX 11,210.34 | 100,000% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | London | Healthcare | Pharmaceuticals | £15.28B | -2,379.2x | 23.64 | GBX 3,482.35 | 39.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Recordati Industria | London | Healthcare | Pharmaceuticals | £9.29B | 26.8x | GBX 4,544.44 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Swedish Orphan Biovitrum publ | London | Healthcare | Pharmaceuticals | £8.18B | 28.3x | 0.54 | GBX 2,369.71 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ipsen L | London | Healthcare | Pharmaceuticals | £7.64B | 27x | -0.56 | GBX 9,295.27 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orion Oyj | London | Healthcare | Pharmaceuticals | £6.32B | 23.1x | 0.44 | GBX 4,483.36 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols Pref | London | Healthcare | Pharmaceuticals | £6.16B | 47.2x | 0.15 | GBX 671.97 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Grifols | London | Healthcare | Pharmaceuticals | £6.16B | 47.2x | 0.15 | GBX 903.94 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hikma Pharma | London | Healthcare | Pharmaceuticals | £4.84B | 21.5x | 0.19 | GBX 2,176 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.2% Upside | Upgrade to Pro+ | |
H Lundbeck L | London | Healthcare | Pharmaceuticals | £4.21B | 13.3x | 0.32 | GBX 442.80 | -77% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Richter Gedeon Vegyeszeti Gyar | London | Healthcare | Pharmaceuticals | £4.05B | 8.3x | 0.03 | GBX 1,029.75 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ALK-ABELLO | London | Healthcare | Pharmaceuticals | £3.70B | 41.3x | 0.6 | GBX 1,671.55 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Camurus | London | Healthcare | Pharmaceuticals | £2.93B | 91.3x | -22.76 | GBX 4,994.90 | 29.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dottikon Es Holding | London | Healthcare | Pharmaceuticals | £2.50B | 37.8x | -2.97 | GBX 18,003.10 | -8.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hutchison China | London | Healthcare | Pharmaceuticals | £2.19B | -66.4x | 7.69 | GBX 257 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Virbac SA | London | Healthcare | Pharmaceuticals | £2.10B | 17.9x | 0.93 | GBX 25,013.02 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Almirall | London | Healthcare | Pharmaceuticals | £1.74B | 205.7x | 1.67 | GBX 811.48 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pharma Mar | London | Healthcare | Pharmaceuticals | £1.44B | 2,850x | GBX 8,226.23 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Fagron NV | London | Healthcare | Pharmaceuticals | £1.11B | 16.8x | 1.21 | GBX 1,538.25 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Indivior | London | Healthcare | Pharmaceuticals | £943.44M | -445x | 0.01 | GBX 753.50 | 7.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cosmo Pharmas | London | Healthcare | Pharmaceuticals | £941.02M | 16.3x | 0.03 | GBX 5,834.58 | 22.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogaia AB | London | Healthcare | Pharmaceuticals | £928.63M | 35.6x | -9.17 | GBX 919.74 | -75.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Faes Farma | London | Healthcare | Pharmaceuticals | £875.69M | 10.9x | GBX 279.02 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Uniphar | London | Healthcare | Pharmaceuticals | £604.66M | 15.9x | 0.26 | GBX 224 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medincell | London | Healthcare | Pharmaceuticals | £391.31M | -13.2x | 1.67 | GBX 1,180.48 | 63.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alliance Pharma | London | Healthcare | Pharmaceuticals | £336.23M | -10x | 0.68 | GBX 62 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.4% Upside | Upgrade to Pro+ | |
Niox PLC | London | Healthcare | Pharmaceuticals | £267.44M | 24.1x | 1.92 | GBX 67.40 | 7.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.9% Upside | Upgrade to Pro+ | |
Beximco Pharma. | London | Healthcare | Pharmaceuticals | £229.15M | 5.5x | 0.19 | GBX 38.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Santhera Pharmas Holding | London | Healthcare | Pharmaceuticals | £177.88M | 2.8x | 0.02 | GBX 1,421.20 | 66.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Animalcare | London | Healthcare | Pharmaceuticals | £157.53M | 7.5x | 0.02 | GBX 228 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.3% Upside | Upgrade to Pro+ | |
Photocure | London | Healthcare | Pharmaceuticals | £100.21M | 101.5x | 0.49 | GBX 365.57 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Venture Life Group | London | Healthcare | Pharmaceuticals | £51.36M | 66.7x | 0.37 | GBX 40.25 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eco Animal | London | Healthcare | Pharmaceuticals | £39.57M | 59.2x | 0.44 | GBX 60 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kala Pharmaceuticals | London | Healthcare | Pharmaceuticals | £33.88M | -0.6x | -0.02 | GBX 549.74 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
bluebird bio | London | Healthcare | Pharmaceuticals | £31.99M | -0.1x | 0 | GBX 646.72 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CRUSHMETRIC | Aquis Exchange | Healthcare | Pharmaceuticals | £30.16M | -4.4x | GBX 12.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |